<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39361431</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1398-9995</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Allergy</Title><ISOAbbreviation>Allergy</ISOAbbreviation></Journal><ArticleTitle>Notch4 regulatory T cells and SARS-CoV-2 viremia shape COVID19 survival outcome.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/all.16333</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immune dysregulation and SARS-CoV-2 plasma viremia have been implicated in fatal COVID-19 disease. However, how these two factors interact to shape disease outcomes is unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We carried out viral and immunological phenotyping on a prospective cohort of 280 patients with COVID-19 presenting to acute care hospitals in Boston, Massachusetts and Genoa, Italy between June 1, 2020 and February 8, 2022. Disease severity, mortality, plasma viremia, and immune dysregulation were assessed. A mouse model of lethal H1N1 influenza infection was used to analyze the therapeutic potential of Notch4 and pyroptosis inhibition in disease outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Stratifying patients based on %Notch4<sup>+</sup> Treg cells and/or the presence of plasma viremia identified four subgroups with different clinical trajectories and immune phenotypes. Patients with both high %Notch4<sup>+</sup> Treg cells and viremia suffered the most disease severity and 90-day mortality compared to the other groups even after adjusting for baseline comorbidities. Increased Notch4 and plasma viremia impacted different arms of the immune response in SARS-CoV-2 infection. Increased Notch4 was associated with decreased Treg cell amphiregulin expression and suppressive function whereas plasma viremia was associated with increased monocyte cell pyroptosis. Combinatorial therapies using Notch4 blockade and pyroptosis inhibition induced stepwise protection against mortality in a mouse model of lethal H1N1 influenza infection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The clinical trajectory and survival outcome in hospitalized patients with COVID-19 is predicated on two cardinal factors in disease pathogenesis: viremia and Notch4<sup>+</sup> Treg cells. Intervention strategies aimed at resetting the immune dysregulation in COVID-19 by antagonizing Notch4 and pyroptosis may be effective in severe cases of viral lung infection.</AbstractText><CopyrightInformation>© 2024 European Academy of Allergy and Clinical Immunology and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benamar</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1532-8642</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Peggy S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ching-Ying</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oktelik</LastName><ForeName>Fatma Betul</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Contini</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Unit of Clinical Immunology and Translational Medicine, University of Genova, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunology Division, IRCCS-San Martino Hospital, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Muyun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okin</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crestani</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Jason</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6164-6110</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fion</LastName><ForeName>Tsz Man Chan</ForeName><Initials>TMC</Initials><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gokbak</LastName><ForeName>Merve Nida</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0002-9220-9455</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harb</LastName><ForeName>Hani</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8218-2538</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Medical Microbiology and Virology, Technical University Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phipatanakul</LastName><ForeName>Wanda</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marri</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Unit of Clinical Immunology and Translational Medicine, University of Genova, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunology Division, IRCCS-San Martino Hospital, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vassallo</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Immunology Division, IRCCS-San Martino Hospital, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guastalla</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Immunology Division, IRCCS-San Martino Hospital, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Minsik</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Hui-Yu</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berra</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Marcia B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8350-8464</Identifier><AffiliationInfo><Affiliation>Istituto per le Applicazioni del Calcolo "M. Picone", Consiglio Nazionale delle Ricerche, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Palma</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Unit of Clinical Immunology and Translational Medicine, University of Genova, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNR-Institute of Biomolecular Chemistry (IBC), Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatila</LastName><ForeName>Talal A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0001-7439-2762</Identifier><AffiliationInfo><Affiliation>Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Deutsche Gesellschaft für Suchtforschung und Suchttherapie</Agency><Country /></Grant><Grant><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Boston Children's Hospital</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Allergy</MedlineTA><NlmUniqueID>7804028</NlmUniqueID><ISSNLinking>0105-4538</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID19</Keyword><Keyword MajorTopicYN="N">Notch4</Keyword><Keyword MajorTopicYN="N">pyroptosis</Keyword><Keyword MajorTopicYN="N">regulatory T cells</Keyword><Keyword MajorTopicYN="N">survival</Keyword><Keyword MajorTopicYN="N">viremia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39361431</ArticleId><ArticleId IdType="doi">10.1111/all.16333</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Dong E, Du H, Gardner L. An interactive web‐based dashboard to track COVID‐19 in real time. Lancet Infect Dis. 2020;20(5):533‐534.</Citation></Reference><Reference><Citation>Msemburi W, Karlinsky A, Knutson V, Aleshin‐Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID‐19 pandemic. Nature. 2023;613(7942):130‐137.</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10):1054‐1062.</Citation></Reference><Reference><Citation>Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta‐analysis. BMC Infect Dis. 2021;21(1):663.</Citation></Reference><Reference><Citation>Fajnzylber J, Regan J, Coxen K, et al. SARS‐CoV‐2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11(1):5493.</Citation></Reference><Reference><Citation>Prebensen C, Myhre PL, Jonassen C, et al. Severe acute respiratory syndrome coronavirus 2 RNA in plasma is associated with intensive care unit admission and mortality in patients hospitalized with coronavirus disease 2019. Clin Infect Dis. 2021;73(3):e799‐e802.</Citation></Reference><Reference><Citation>Hogan CA, Stevens BA, Sahoo MK, et al. High frequency of SARS‐CoV‐2 RNAemia and association with severe disease. Clin Infect Dis. 2021;72(9):e291‐e295.</Citation></Reference><Reference><Citation>Genc AB, Yaylaci S, Dheir H, et al. The predictive and diagnostic accuracy of long pentraxin‐3 in COVID‐19 pneumonia. Turk J Med Sci. 2021;51(2):448‐453.</Citation></Reference><Reference><Citation>Brunetta E, Folci M, Bottazzi B, et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID‐19. Nat Immunol. 2021;22(1):19‐24.</Citation></Reference><Reference><Citation>Lapadula G, Leone R, Bernasconi DP, et al. Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID‐19. Front Immunol. 2022;13:933960.</Citation></Reference><Reference><Citation>Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID‐19. Nature. 2020;584(7821):463‐469.</Citation></Reference><Reference><Citation>Hammond J, Leister‐Tebbe H, Gardner A, et al. Oral Nirmatrelvir for high‐risk, nonhospitalized adults with Covid‐19. N Engl J Med. 2022;386(15):1397‐1408.</Citation></Reference><Reference><Citation>Chen P, Nirula A, Heller B, et al. SARS‐CoV‐2 neutralizing antibody LY‐CoV555 in outpatients with Covid‐19. N Engl J Med. 2021;384(3):229‐237.</Citation></Reference><Reference><Citation>Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS‐CoV‐2 neutralizing antibodies. Nature. 2022;602(7898):657‐663.</Citation></Reference><Reference><Citation>Group WHOREAfC‐TW, Sterne JAC, Murthy S, et al. Association between Administration of Systemic Corticosteroids and Mortality among Critically ill Patients with COVID‐19: a meta‐analysis. JAMA. 2020;324(13):1330‐1341.</Citation></Reference><Reference><Citation>Group WHOREAfC‐TW, Shankar‐Hari M, Vale CL, et al. Association between administration of IL‐6 antagonists and mortality among patients hospitalized for COVID‐19: a meta‐analysis. JAMA. 2021;326(6):499‐518.</Citation></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid‐19. N Engl J Med. 2021;384(9):795‐807.</Citation></Reference><Reference><Citation>Kaka AS, MacDonald R, Linskens EJ, et al. Major update 2: Remdesivir for adults with COVID‐19: a living systematic review and meta‐analysis for the American College of Physicians Practice Points. Ann Intern Med. 2022;175(5):701‐709.</Citation></Reference><Reference><Citation>Carbonell R, Urgeles S, Rodriguez A, et al. Mortality comparison between the first and second/third waves among 3,795 critical COVID‐19 patients with pneumonia admitted to the ICU: a multicentre retrospective cohort study. Lancet Reg Health Eur. 2021;11:100243.</Citation></Reference><Reference><Citation>Moore JB, June CH. Cytokine release syndrome in severe COVID‐19. Science. 2020;368(6490):473‐474.</Citation></Reference><Reference><Citation>Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid‐19. N Engl J Med. 2021;384(8):693‐704.</Citation></Reference><Reference><Citation>Griffith JW, Faustino LD, Cottrell VI, et al. Regulatory T cell‐derived IL‐1Ra suppresses the innate response to respiratory viral infection. Nat Immunol. 2023;24(12):2091‐2107.</Citation></Reference><Reference><Citation>Georgiev P, Benamar M, Han S, Haigis MC, Sharpe AH, Chatila TA. Regulatory T cells in dominant immunologic tolerance. J Allergy Clin Immunol. 2024;153(1):28‐41.</Citation></Reference><Reference><Citation>Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science. 2008;320(5880):1220‐1224.</Citation></Reference><Reference><Citation>Arpaia N, Green JA, Moltedo B, et al. A distinct function of regulatory T cells in tissue protection. Cell. 2015;162(5):1078‐1089.</Citation></Reference><Reference><Citation>Burzyn D, Kuswanto W, Kolodin D, et al. A special population of regulatory T cells potentiates muscle repair. Cell. 2013;155(6):1282‐1295.</Citation></Reference><Reference><Citation>Harb H, Benamar M, Lai PS, et al. Notch4 signaling limits regulatory T‐cell‐mediated tissue repair and promotes severe lung inflammation in viral infections. Immunity. 2021;54(6):1186.</Citation></Reference><Reference><Citation>Vick SC, Frutoso M, Mair F, et al. A regulatory T cell signature distinguishes the immune landscape of COVID‐19 patients from those with other respiratory infections. Sci Adv. 2021;7(46):eabj0274</Citation></Reference><Reference><Citation>Galvan‐Pena S, Leon J, Chowdhary K, et al. Profound Treg perturbations correlate with COVID‐19 severity. Proc Natl Acad Sci USA. 2021;118(37):e2111315118 .</Citation></Reference><Reference><Citation>Gladstone DE, Kim BS, Mooney K, Karaba AH, D'Alessio FR. Regulatory T cells for treating patients with COVID‐19 and acute respiratory distress syndrome: two case reports. Ann Intern Med. 2020;173(10):852‐853.</Citation></Reference><Reference><Citation>Raffin C, Vo LT, Bluestone JA. Treg cell‐based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158‐172.</Citation></Reference><Reference><Citation>Benamar M, Harb H, Chen Q, et al. A common IL‐4 receptor variant promotes asthma severity via a Treg cell GRB2‐IL‐6‐Notch4 circuit. Allergy. 2022;77:3377‐3387.</Citation></Reference><Reference><Citation>Harb H, Stephen‐Victor E, Crestani E, et al. A regulatory T cell Notch4‐GDF15 axis licenses tissue inflammation in asthma. Nat Immunol. 2020;21(11):1359‐1370.</Citation></Reference><Reference><Citation>Junqueira C, Crespo A, Ranjbar S, et al. FcgammaR‐mediated SARS‐CoV‐2 infection of monocytes activates inflammation. Nature. 2022;606(7914):576‐584.</Citation></Reference><Reference><Citation>Sefik E, Qu R, Junqueira C, et al. Inflammasome activation in infected macrophages drives COVID‐19 pathology. Nature. 2022;606:585‐593.</Citation></Reference><Reference><Citation>Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid‐19. N Engl J Med. 2020;383(18):1757‐1766.</Citation></Reference><Reference><Citation>He WT, Wan H, Hu L, et al. Gasdermin D is an executor of pyroptosis and required for interleukin‐1beta secretion. Cell Res. 2015;25(12):1285‐1298.</Citation></Reference><Reference><Citation>Kayagaki N, Stowe IB, Lee BL, et al. Caspase‐11 cleaves gasdermin D for non‐canonical inflammasome signalling. Nature. 2015;526(7575):666‐671.</Citation></Reference><Reference><Citation>Cai W, Wu Z, Lai J, et al. LDC7559 inhibits microglial activation and GSDMD‐dependent pyroptosis after subarachnoid hemorrhage. Front Immunol. 2023;14:1117310.</Citation></Reference><Reference><Citation>Ho LC, Chen YH, Wu TY, et al. Phosphate burden induces vascular calcification through a NLRP3‐caspase‐1‐mediated pyroptotic pathway. Life Sci. 2023;332:122123.</Citation></Reference><Reference><Citation>Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin‐1 production and inflammasome activation. Immunity. 2011;34(2):213‐223.</Citation></Reference><Reference><Citation>Bawazeer AO, Rosli S, Harpur CM, Docherty CA, Mansell A, Tate MD. Interleukin‐1beta exacerbates disease and is a potential therapeutic target to reduce pulmonary inflammation during severe influenza a virus infection. Immunol Cell Biol. 2021;99(7):737‐748.</Citation></Reference><Reference><Citation>Seyedsadr M, Wang Y, Elzoheiry M, et al. IL‐11 induces NLRP3 inflammasome activation in monocytes and inflammatory cell migration to the central nervous system. Proc Natl Acad Sci USA. 2023;120(26):e2221007120.</Citation></Reference><Reference><Citation>Wang H, Wang Z, Wang L, et al. IL‐6 promotes collagen‐induced arthritis by activating the NLRP3 inflammasome through the cathepsin B/S100A9‐mediated pathway. Int Immunopharmacol. 2020;88:106985.</Citation></Reference><Reference><Citation>Todorovic‐Rakovic N, Whitfield JR. Between immunomodulation and immunotolerance: the role of IFNgamma in SARS‐CoV‐2 disease. Cytokine. 2021;146:155637.</Citation></Reference><Reference><Citation>Krishna BA, Lim EY, Metaxaki M, et al. Spontaneous, persistent, T cell‐dependent IFN‐gamma release in patients who progress to long Covid. Sci Adv. 2024;10(8):eadi9379.</Citation></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID‐19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420‐422.</Citation></Reference><Reference><Citation>Hasan MZ, Islam S, Matsumoto K, Kawai T. SARS‐CoV‐2 infection initiates interleukin‐17‐enriched transcriptional response in different cells from multiple organs. Sci Rep. 2021;11(1):16814.</Citation></Reference><Reference><Citation>Cafarotti S. Severe acute respiratory syndrome‐Coronavirus‐2 infection and patients with lung cancer: the potential role of Interleukin‐17 target therapy. J Thorac Oncol. 2020;15(7):e101‐e103.</Citation></Reference><Reference><Citation>Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science. 2012;335(6071):936‐941.</Citation></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life‐threatening COVID‐19. Science. 2020;370(6515):eabd4570.</Citation></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life‐threatening COVID‐19. Science. 2020;370(6515):eabd4585.</Citation></Reference><Reference><Citation>Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255‐2273.</Citation></Reference><Reference><Citation>Investigators R‐C, Gordon AC, Mouncey PR, et al. Interleukin‐6 receptor antagonists in critically ill patients with Covid‐19. N Engl J Med. 2021; 384(16):1491‐1502.</Citation></Reference><Reference><Citation>Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID‐19 (COV‐BARRIER): a randomised, double‐blind, parallel‐group, placebo‐controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407‐1418.</Citation></Reference><Reference><Citation>Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID‐19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double‐blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752‐1760.</Citation></Reference><Reference><Citation>group C‐C. Effect of anakinra versus usual care in adults in hospital with COVID‐19 and mild‐to‐moderate pneumonia (CORIMUNO‐ANA‐1): a randomised controlled trial. Lancet. Respir Med. 2021;9(3):295‐304.</Citation></Reference><Reference><Citation>Li J, Liao X, Zhou Y, et al. Association between glucocorticoids treatment and viral clearance delay in patients with COVID‐19: a systematic review and meta‐analysis. BMC Infect Dis. 2021;21(1):1063.</Citation></Reference><Reference><Citation>Tang K, Wu L, Luo Y, Gong B. Quantitative assessment of SARS‐CoV‐2 RNAemia and outcome in patients with coronavirus disease 2019. J Med Virol. 2021;93(5):3165‐3175.</Citation></Reference><Reference><Citation>Brun‐Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L, Group R‐SAHNvR. Early corticosteroids in severe influenza a/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183(9):1200‐1206.</Citation></Reference><Reference><Citation>Subbarao K, Mahanty S. Respiratory virus infections: understanding COVID‐19. Immunity. 2020;52(6):905‐909.</Citation></Reference><Reference><Citation>Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS‐CoV‐2 in an immunocompromised host. N Engl J Med. 2020;383(23):2291‐2293.</Citation></Reference><Reference><Citation>Meckiff BJ, Ramirez‐Suastegui C, Fajardo V, et al. Imbalance of regulatory and cytotoxic SARS‐CoV‐2‐reactive CD4(+) T cells in COVID‐19. Cell. 2020;183(5):1340‐5316.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>